PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neuron. Author manuscript; available in PMC 2009 August 28.
Published in final edited form as:
PMCID: PMC2628490
NIHMSID: NIHMS68078

Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system

Abstract

Understanding the control of myelin formation by oligodendrocytes is essential for treating demyelinating diseases. Neuregulin-1 (NRG1) type III, an EGF-like growth factor, is essential for myelination in the PNS. It is thus thought that NRG1/ErbB signaling also regulates CNS myelination, a view suggested by in vitro studies and the overexpression of dominant-negative ErbB receptors. To directly test this hypothesis, we generated a series of conditional null mutants that completely lack NRG1 beginning at different stages of neural development. Unexpectedly, these mice assemble normal amounts of myelin. In addition, double-mutants lacking oligodendroglial ErbB3 and ErbB4 become myelinated in the absence of any stimulation by neuregulins. In contrast, a significant hypermyelination is achieved by transgenic overexpression of NRG1 type I or NRG1 type III. Thus, NRG1/ErbB signaling is markedly different between Schwann cells and oligodendrocytes that have evolved a NRG/ErbB-independent mechanism of myelination control.

Introduction

The neuronal growth factor Neuregulin-1 (NRG1) comprises a family of more than 15 transmembrane and secreted proteins, derived from one of the largest mammalian genes. All NRG1 subtypes share an epidermal growth factor (EGF)-like signaling domain and can be classified into subgroups through their different amino-termini (Falls, 2003). NRG1 isoforms type I and type II have N-terminal Ig-like domains and, following proteolytic cleavage, can be shed and released as soluble proteins from the neuronal cell surface. NRG1 type III is defined by a cysteine-rich domain (CRD), has two transmembrane domains, and is tightly associated with axonal membranes (Esper et al., 2006; Nave and Salzer, 2006).

The best understood function of NRG1 is the control of myelination in the peripheral nervous system (PNS), where NRG1 is essential for glial and neuronal survival, the proliferation of Schwann cells, and their terminal differentiation (Garratt et al., 2000a; Nave and Salzer, 2006). In development, a threshold level of axonal Nrg1 type III is required to induce myelination by Schwann cells in vitro and in vivo (Taveggia et al., 2005)(Schwab et al., unpublished data). Both Schwann cell expansion and myelination requires glial ErbB2 receptors (Garratt et al., 2000b). Subsequently, the amount of NRG1 type III expressed on myelinated axons determines myelin sheath thickness (Michailov et al., 2004). At this stage, proteolytic processing may be required to fully activate NRG1 type III (Hu et al., 2006; Sagane et al., 2005; Willem et al., 2006).

In the central nervous system (CNS), NRG1/ErbB signaling has been implicated in a broad range of roles including neuronal migration, axonal pathfinding, and synaptic function (Flames et al., 2004; Lopez-Bendito et al., 2006; Mei and Xiong, 2008). NRG1 signaling also affects oligodendrocyte specification, differentiation, myelination, and survival, at least in vitro (Calaora et al., 2001; Canoll et al., 1999; Canoll et al., 1996; Flores et al., 2000; Vartanian et al., 1997).

The embryonic lethality of null mutations has hampered the in vivo analysis of Nrg1 and ErbB in the nervous system (Adlkofer and Lai, 2000; Garratt et al., 2000b). Nevertheless, several ex vivo studies supported a possible role of both genes in oligodendrocyte differentiation and myelination (Fernandez et al., 2000; Park et al., 2001; Sussman et al., 2005; Vartanian et al., 1999). Moreover, heterozygous NRG1 type III mutants were reported to be hypomyelinated (Taveggia et al., 2008), and transgenic mice overexpressing dominant-negative ErbB receptors in oligodendrocytes (Kim et al., 2003; Roy et al., 2007) suggested a critical function of NRG1/ErbB signaling in CNS myelination.

Independently, the identification of Nrg1 as a susceptibility gene in human schizophrenia (Law et al., 2006; Stefansson et al., 2002) has renewed interest in the contribution of NRG1/ErbB signaling to mammalian brain development, including CNS myelination, as some patients with schizophrenia show white matter abnormalities (Corfas et al., 2004). In addition, the demonstration of a myelin-promoting function of NRG1 in vivo could aid the development of a therapeutic strategy for demyelinating diseases such as multiple sclerosis.

To determine the consequences of altered NRG1/ErbB signaling on brain development, and specifically on the myelination of CNS fiber tracts, we generated and analyzed a large battery of mice with either reduced Nrg1 gene dosage, neuronal NRG1 overexpression, various conditional Nrg1 null mutations (defined by Cre-recombination at different stages of development), and mice lacking oligodendroglial ErbB3 and ErbB4 receptors. Collectively, these data demonstrate that axonal NRG1/ErbB signaling plays a fundamentally different role in central and peripheral myelination.

Results

Many CNS axons are first myelinated by oligodendrocytes and then by Schwann cells as they exit the spinal cord. Schwann cells can also invade the demyelinated CNS and ensheath central axons. These observations suggest that the axonal signals controlling myelin formation are conserved in the central and peripheral nervous systems (Colello and Pott, 1997; Duncan and Hoffman, 1997). Since heterozygous Nrg1 null (affecting all isoforms) mice exhibit a significant hypomyelination of axons in the PNS (Michailov et al., 2004; Taveggia et al., 2005), we anticipated a corresponding hypomyelination also in CNS white matter tracts. Surprisingly, analysis of the optic nerve, corpus callosum, and spinal cord of adult Nrg1 null heterozygous (+/−) mice revealed no such reduction of myelin sheath thickness by electron microscopy (Fig. S1A) and subsequent calculation of g-ratios, when plotted as a function of the axonal caliber (Fig. S1B). Also mice heterozygous for only the NRG1 type III isoform (Wolpowitz et al., 2000) exhibited normal myelin thickness in the corpus callosum (Fig. S1C, D). Both findings are at variance with a recent report (Taveggia et al., 2008) published while this manuscript was in revision. Supportive evidence for our findings (in addition to the data below) is that heterozygous mice of either mutant allele (Nrg1 null or type III-specific) express the same steady-state level of NRG1 protein in brain (Fig. S1E) and spinal cord (not shown) when compared to wildtype controls.

Myelination in the absence of NRG1

Conventional Nrg1 null (−/−) mice die at embryonic (E) day 10.5, prior to the generation of oligodendrocytes. We therefore generated conditional null mutants to analyze possible defects of postnatal CNS myelination. Mice carrying two ‘floxed’ Nrg1 alleles readily recombine exons 7–9 (essential for the EGF-like signaling function) upon Cre expression in vivo (Li et al., 2002).

By cross-breeding floxed Nrg1 to CamKII-Cre mice (Minichiello et al., 1999), we obtained mutants lacking NRG1 in virtually all projection neurons of the forebrain (Fig. S2A, B) due to Cre recombination at around postnatal day (P) 5, i.e. after oligodendrocyte specification but prior to subcortical myelination. Surprisingly, these mutants revealed no obvious developmental abnormalities of the cortex, hippocampus, or the subcortical white matter, and showed no demyelination at older age (Fig. S2C, D). A detailed behavioral analysis of these mice will be published elsewhere. Although some myelination may have occurred prior to the complete loss of NRG1 protein, we conclude that axonal NRG1 is not required to maintain CNS myelin throughout adult life.

In order to address the developmental role of NRG1, we generated mutants using Cre recombination during the embryonic period. By cross-breeding floxed Nrg1 with NEX-Cre mice (Goebbels et al., 2006), we disrupted NRG1 expression in newborn projection neurons of the cortex beginning at E12, including virtually all neurons that extend axons into the corpus callosum (Fig. S2E).

Surprisingly, NEX-Cre*Nrg1flox/flox mutants (‘NC*FF’) were fully viable and indistinguishable in the cage from wildtype, floxed (‘FF’), or NEX-Cre*Nrg1flox/+ controls. By morphological and immunohistochemical criteria, the cortex and hippocampus appeared normal (Fig. 1A and data not shown). Efficient Cre-mediated recombination was demonstrated by PCR analysis of brain genomic DNA at 3 months of age (not shown). Quantitative RT-PCR (not shown) and Western blotting (Fig. 1B) confirmed the reduction of NRG1, with residual expression most likely derived from glia (Esper et al., 2006). The subcortical white matter with callosal axons from the overlying cortical projection neurons was well developed (Fig. 1A) and myelin proteins were expressed at wildtype levels (Fig. 1C). We observed that myelinated fibers in the grey matter were normal in appearance when immunostained for 2′ 3′-cyclic nucleotide phosphodiesterase (CNP) (Fig. 1D, E) or MBP (not shown).

Figure 1
Myelination in NEX-Cre*Nrg1flox/flox mice following embryonic recombination

Using electron microscopy, myelin in the corpus callosum and the spinal cord (not shown) of 11 weeks old mice exhibited an intact ultrastructure (Fig. 2A). There were no obvious differences in myelin sheath thickness or axonal size distribution (Fig. 2B). Also at two years of age, there were no signs of hypomyelination, demyelination, or axonal degeneration in these mice, as demonstrated by electron microscopy of the corpus callosum (Fig. 2C, D).

Figure 2
Myelination and myelin ultrastructure in the absence of NRG1

To address a potential myelination delay in the absence of NRG1 we immunostained MBP at postnatal day (P) 10. Confocal microscopy revealed unaltered numbers of MBP+ myelin profiles in the ventral corpus callosum of NC*FF mutants when compared to controls (Fig. 2E, F), demonstrating that also timely myelination does not depend on NRG1.

Recently, hypomyelination in the CNS was reported in mice lacking the expression of BACE1, a protease required for NRG1 processing (Hu et al., 2006; Willem et al., 2006). This suggests that widespread BACE1 activity could provide a "paracrine" source of NRG1 originating from astrocytes (Esper et al., 2006) that are genetically ‘wildtype’ in NEX-Cre*NRG1flox/flox mice.

To inactivate possible astroglial and oligodendroglial sources of NRG1 in the developing CNS, we generated conditional Emx-Cre*Nrg1flox/flox null mutants that recombine efficiently in multipotential progenitors of the embryonic forebrain (Gorski et al., 2002). When analyzed at adult age (4 months), these mice were fullly myelinated (not shown) without morphological or biochemical differences between wildtype and mutants (Fig S3A, B), exept for the nearly complete absence of NRG1 in brain lysates (not shown).

To completely abolish NRG1 expression in the developing CNS, we generated conditional mutants using Nestin-Cre mice (Tronche et al., 1999) (Fig. S4A, B). Nestin-Cre*Nrg1flox/flox mutants died about 16h after birth, i.e. later than conventional Nrg1 type III null mutants (Wolpowitz et al., 2000) but most likely with a lethal PNS defect (see below and Fig. S4C, D). When Nestin-Cre mutants were analyzed at birth, there was no detectable difference in brain morphology compared to controls (Fig. 3A). Western blotting showed mutant brains to be almost completely NRG1-deficient (Fig. 3B, top). Also in spinal cord, NRG1 was dramatically reduced (Fig. 3B, bottom). Quantitative RT-PCR confirmed the virtual absence of NRG1 in brain and a severe reduction in spinal cord, with residual protein expression most likely derived from the central branch of inefficiently recombined DRG neurons (Fig. S4B). Spinal cord ventral roots, harboring the peripheral aspects of motoneuron axons, as well as intercostal nerves, almost completely lacked MBP and MPZ (P0) immunostaining, demonstrating a block of Schwann cell differentiation in Nestin-Cre*Nrg1flox/flox mutants (Fig. 3C, middle and bottom panel). Accordingly, immunostaining of sciatic nerves derived from newborn Nestin-Cre*Nrg1flox/flox mice revealed a strong reduction in the number of MPZ-stained myelin profiles and Krox20-stained myelinating Schwann cells (Fig. S4C, D).

Figure 3
Oligodendrocytes develop on schedule in the absence of NRG1

Unexpectedly, the density of Olig2+ and MBP+ oligodendrocytes in the forebrain and spinal cord of these mice (Fig. 3D and not shown) did not obviously differ in mutants and controls (not quantified). Similary, in the spinal cord, there was no difference in the density of MBP+ myelin profiles in Nestin-Cre*Nrg1flox/flox mice at birth (Fig. 3C, upper panel). While these data do not rule out a function for NRG1 as a growth or survival factor in the oligodendrocyte lineage, myelinating glial cells clearly develop in the absence of NRG1 in vivo.

Since Nestin-Cre*Nrg1flox/flox mice died many days prior to myelin formation in the subcortical white matter, we also compared long-term co-cultures of wildtype oligodendrocytes and cortical neurons, derived from embryonic wildtype or Nrg1 null mice. As expected, myelination of the NRG1-deficient CNS axons could be readily demonstrated by MBP immunostaining (Fig. S5A), and was independently observed in mixed brain cultures derived solely from Nestin-Cre*Nrg1flox/flox mice (Fig. S5B).

Myelination in the absence of ErbB signaling

The receptor tyrosine kinases ErbB2 and ErbB4 have been suggested to control CNS myelination in vivo (Vartanian et al., 1997), while ErbB3 is not required for oligodendrocytic differentiation (Schmucker et al., 2003).

We first studied myelination in mice that lacked ErbB4, but were rescued from embryonic lethality by means of a MHC-ErbB4 transgene expressed in the heart (Tidcombe et al., 2003). Myelination appeared normal in the CNS of these ErbB4-mutant mice, and there was no paucity of Olig2+ oligodendrocytes (data not shown). By electron microscopy homozygous ErbB4 null mutants had no dysmyelination phenotype (Fig. 4A). When quantified in the corpus callosum, g-ratios of myelinated axons in ErbB4 null mutant mice were the same as in controls (Fig. 4B).

Figure 4
Myelination in the absence of ErbB3 and ErbB4 receptors

All neuregulins (NRG1, NRG2, NRG3) signal via ErbB2, ErbB3, and ErbB4 receptor homo/heterodimers. Since ErbB2 lacks a ligand-binding activity, the absence of both ErbB4 and ErbB3 from oligodendrocytes should suffice to completely eliminate neuregulin signaling. We therefore generated a floxed allele of the erbB3 gene (TM, HW, and CB, unpublished data) and crossed these conditional mutants to a conditional null mutant of the erbB4 gene (Golub et al., 2004). Efficient recombination of both genes in oligodendrocytes using CNP-Cre mice (Lappe-Siefke et al., 2003) was confirmed by PCR on genomic DNA derived from cortex and optic nerve (data not shown). As expected, we detected by quantitative real time PCR a severe reduction in ErbB3 and ErbB4 expression in various CNS regions (including optic nerve; Fig. S3C, D) with residual mRNA most likely derived from non-oligodendroglial cells.

CNP-Cre*ErbB3flox/− single mutants (harbouring one copy of the conventional erbB3 null allele; Riethmacher et al., 1997) and CNP-Cre*ErbB3flox/−*ErbB4flox/flox double mutants developed to term. As expected, they displayed severe defects in PNS myelination (Fig. 4C; bottom panel) and died in the second postnatal week. In striking contrast, electron microscopy of the optic nerve and corpus callosum (Fig. 4C; upper and middle panel), g-ratio measurements (Fig. 4D: optic nerve only), and immunostaining for MBP (not shown) clearly demonstrated that oligodendrocytes in ErbB3*ErbB4 double mutants (CNP-Cre*ErbB3flox/−*ErbB4flox/flox) were capable of myelinating CNS axons without delay and at the same level as control mice (ErbB3flox/+*ErbB4flox/+), at least up to postnatal day P11. Although we can not rule out phenotypic differences at later stages, we conclude that neuregulin/ErbB signaling is dispensable for CNS myelination in vivo.

Myelination in response to NRG1 type I and type III overexpression

While myelination is independent of NRG1 in vivo, cells of the oligodendrocyte lineage clearly respond to the soluble growth factor in culture (Calaora et al., 2001; Fernandez et al., 2000; Flores et al., 2000; Kim et al., 2003; Vartanian et al., 1999; Vartanian et al., 1997). To determine what type of responsiveness oligodendrocytes show to axonal NRG1 in vivo, we analyzed mice that overexpress cDNAs encoding NRG1 type III (or NRG1 type I) under control of the neuronal Thy1.2 promoter (Michailov et al., 2004). All NRG1 overexpressing mice were viable, but those with higher transgene dosage exhibited ataxia that was most pronounced in homozygous mice and that precluded detailed behavioural testing (not shown). The cause of these neurological abnormalities is unknown, but given the broad expression of NRG1 and ErbB receptors, it could be due to abnormal neuronal differentiation, synaptic function, myelination, muscle development, or any combination of these. By immunocytochemical analyses, the overexpression of NRG1 type I or NRG1 type III was widespread throughout the cortex in all lines tested (Fig. S6A, and data not shown). By quantitative RT-PCR analysis (Fig. S6B) and Western blotting (Fig. S6C), NRG1 steady state levels were about 5-fold increased in adult heterozygous Thy1-Nrg1 type I and type III transgenic mice.

Although morphological effects were not dramatic, we found many "hypermyelinated" axons in the white matter regions analyzed. By electron microscopy, these axon-myelin units were regularly spaced and hypermyelination was clearly the result of additional spiral wraps (Fig. 5A). Unexpectedly, decreased g-ratios were also observed in Nrg1 type I transgenic mice (Fig. 5B), not only in type III transgenics (Fig. 5C). This revealed an important difference between the CNS and PNS, where only the overexpression of axon-bound NRG1 type III induces hypermyelination (Michailov et al., 2004). It is conceivable that (shed) NRG1 type I acts by stimulating oligodendrocyte production prior to myelination, and that an altered axon-glia ratio is the basis of hypermyelination. We therefore compared the density of CC1+ and CNP+ oligodendrocytes within the corpus callosum of type I transgenic and wildtype mice, but found no significant differences (Fig. S6D and data not shown).

Figure 5
Transgenic overexpression of NRG1 type I or type III causes hypermyelination

Also axons within the cortex (layers II and III), which are generally of small calibre, showed a significant decrease of g-ratios (Fig. 6A, B). In Nrg1 type I transgenics, such a hypermyelination was only a feature of axons thinner than 0.4 µm (leading to a crossing of regression lines). Interestingly, in both transgenic lines, we noticed a 2-fold increase of myelinated fibers per cross sectional area (upper cortical layers; white arrowheads in Fig. 6C) when compared to controls (Fig. 6D). However, there was no corresponding increase in the density of (CC1+) oligodendrocytes (Fig. 6E).

Figure 6
Transgenic overexpression of NRG1 type I or NRG1 type III stimulates myelination in neocortex

Possible explanations for the 2-fold higher "myelin-to-oligodendrocyte" ratio in the cortex could be an increase of internodal length and/or a higher number of internodes (i.e. oligodendrocyte processes) in NRG1 overexpressing mice. Since an unbiased quantitation of internodal length is difficult within cortical sections, we performed confocal microscopy and three-dimensional cell tracing of selected, singly located (CNP-stained) oligodendrocytes in layers II and III of the cingulate and primary motor cortex (Fig. 7A). In the absence of pathological signs, the avarage number of processes (Fig 7B), process branch points (Fig 7C), and process length including internodal myelin (Fig 7D) was not significantly altered in Nrg1 mutants and NRG1 type III overexpressing mice. Only the average ‘territory’ of these oligodendrocytes (Fig 7E) was significantly higher in transgenics (+50%), similar to the increased volume of the oligodendroglial somata (Fig 7F). Thus, cortical hypermyelination cannot be fully explained by a numerical increase of oligodendrocyte processes in the cortex of NRG1 type III overexpressing mice. Outside the cortex, we never found "ectopic" ensheathment of axons that normally remain unmyelinated (such as mossy fibers in the hippocampus), although in transgenic mice dentate gyrus granule cells expressed visibly more NRG1 (data not shown).

Figure 7
Oligodendrocyte morphology

While myelination was not delayed even in the absence of NRG1 (Fig 2E, F), there was clear evidence for premature myelination in NRG1 type III overexpressing mice (Fig. 8A). For example, Nrg1 mRNA in retinal ganglion cells was further enhanced in early postnatal mice by expression of the ThyI-Nrg1 type III transgene (Fig. 8B, C). In these developing optic nerves, we determined a 3-fold higher number of myelinated axons than in controls (day P6; Fig 8D), without a corresponding shift of oligodendrocyte numbers (Fig. 8E). This demonstrates that NRG1 can initiate the myelination program in CNS development, a function normally provided by a distinct (yet unknown) axonal signalling system. We also conclude from this unexpected result that in normal development the onset of CNS myelination is likely determined by the degree of neuronal differentiation, and not by the timing of an intrinsic oligodendrocyte differentiation program.

Figure 8
NRG1 type III stimulates premature myelination of the optic nerve

CNS remyelination in NRG1 type I and III overexpressing mice

To test whether NRG1 would have a similar stimulating effect on CNS remyelination, we induced focal demyelination by injecting lysolecthin into the ventro-lateral region of the spinal cord. Surprinsingly, while axons in Nrg1 overexpressing mice were clearly hypermyelinated on the contra-lateral side (Fig S7A), the extent of axonal remyelination in the lesion, when quantified by electron microscopy, was no different between Nrg1 type I transgenic, Nrg1 type III transgenic, and wild-type mice (Fig. S7B–D). This is reminiscent of experiments, in which both direct infusion and systemic delivery of rhGGF-2 (Nrg1 type II) do not alter remyelination (Penderis et al., 2003) in a nonimmune, gliotoxin model of demyelination. Interestingly, in lesions of Nrg1 type III tg mice Schwann cell remyelination showed hypermyelination in line with earlier observations in the PNS (Michailov et al., 2004).

Discussion

In the PNS, the entire program of glial differentiation and myelination is controlled by NRG1 type III (Garratt et al., 2000a; Jessen and Mirsky, 2005; Nave and Salzer, 2006), and many studies have reported that oligodendrocytes respond to NRG1 in vitro and ex vivo (Calaora et al., 2001; Canoll et al., 1996; Fernandez et al., 2000; Flores et al., 2000; Sussman et al., 2005; Vartanian et al., 1999; Vartanian et al., 1997). This suggested that NRG1 may also be the growth factor responsible for regulating CNS myelination, a finding that would have important clinical implications. In multiple sclerosis the endogenous repair of demyelinated lesions could be NRG1 dependent (ffrench-Constant et al., 2004). Moreover, schizophrenia is a complex disease that has been associated with specific NRG1 haplotypes (Hall et al., 2006; Stefansson et al., 2002) and independently with myelin abnormalties (Davis et al., 2003; Hakak et al., 2001). Thus, the control of subcortical myelination by NRG1 could be a missing link (Corfas et al., 2004).

The role of neuregulins and ErbB receptors in myelination

Using a large set of mutant and transgenic mice, we have analyzed the function of NRG1/ErbB signaling in oligodendrocytic differentiation and myelination in vivo. We quantified the impact of altered Nrg1 gene dosage and studied mutants with Cre-mediated Nrg1 null mutations in cortical projection neurons, occurring either before or after oligodendrocytic specification, i.e. at E10 (Emx-Cre), E12 (NEX-Cre) or at P5 (CamKII-Cre). Contrary to our expectations, the complete absence of neuronal NRG1 did not perturb oligodendrocyte development and myelination in vivo. Even Nestin-Cre*NRG1flox/flox mice exhibited normal specification of oligodendrocytes that developed on schedule (Fig. 3) until early demise of these animals (the cause of death is presumably unrelated to CNS myelination).

At the receptor level, only ErbB3 and ErbB4 can bind to neuregulins (NRG1-3). ErbB1/EGFR can regulate oligodendrocyte precursor development (Aguirre et al., 2007), but fails to bind neuregulins. ErbB2 has no functional ligand-binding domain. Thus, oligodendrocytes lacking both ErbB3 and ErbB4 are incapable of transmitting signals from NRG1, NRG2, or NRG3. Most importantly, these double-mutant oligodendrocytes survive and myelinate CNS axons in vivo, in marked contrast to double-mutant Schwann cells (Fig. 4). This finding demonstrates that, indeed, neuregulin signaling is dispensible for CNS myelination, at least during postnatal stages.

Our results are at odds with previous reports which suggested that NRG1 is required for oligodendrocyte survival and differentiation in culture (Calaora et al., 2001; Canoll et al., 1996; Flores et al., 2000; Kim et al., 2003; Sussman et al., 2005; Vartanian et al., 1997). Specifically, the discrepancy between the present in vivo study and previous ex vivo analyses of null mutant mice is intriguing. Oligodendrocytes from Nrg1 null or ErbB2 null mutant mice failed to differentiate within spinal cord explants (Vartanian et al., 1999; Park et al., 2001). We have currently no explanation for these findings other than a speculative model that the electrical activity of axons may have evolved as a ‘myelination signal’ in the CNS. Perhaps, in explant cultures NRG1/ErbB signaling (i.e. the ancestral axonal myelination signal) can compensate for the absence of electrical activity in axons - but obviously not in cultures obtained from Nrg1 or ErbB mutant mice.

Recently, Taveggia et al. (2008) reported cortical hypomyelination in Nrg1 type III heterozygous mice (Wolpowitz et al., 2000). This presents a discrepancy with our findings in the same strain of mutants (see Fig. S1C, D), as well as in Nrg1 null heterozygotes (Fig. S1A, B; all on C57BL background) and remains also unexplained. Our data are supported by unaltered NRG1 protein level in the brains of heterozygote Nrg1 (type III and null mutant) mice (Fig. S1E) and the phenotype of various conditional null mutant mice. The effect of modifier genes in different mouse colonies could potentially explain such discrepancies.

Also reports of CNS hypomyelination in mice overexpressing ‘dominant-negative’ ErbB proteins under control of oligodendrocyte-specific promoters (Kim et al., 2003; Roy et al., 2007) are at variance with our findings. Unspecific side effects are the most likely explanation. For example, dominant-negative ErbB4 interacts with ErbB1/EGFR (Jones et al., 1999), a receptor regulating the development of oligodendrocyte precursor cells (Aguirre et al., 2007). Truncated ErbB receptors may also ‘trap’ wildtype ErbB4 at specific sites in the glial-axonal junction (since mutant heterodimers will not endocytose at the normal rate). Truncated receptor dimers may occupy PDZ binding sites or simply displace other (not yet identified) oligodendroglial receptors, which then fail to transmit axonal signals, all of which would constitute a ‘dominant-negative’ effect. We finally note the general susceptibilty of oligodendrocytes to membrane protein overexpression (Kagawa et al., 1994; Readhead et al., 1994; Tuohy et al., 2004; Turnley et al., 1991), because the expression level of dominant-negative receptors in transgenic oligodendrocytes can not be predicted from the chosen promoter.

Can our in vivo results be explained by functional compensation between NRG1 and the structurally related growth factor Neuregulin-2 (NRG2) (Carraway et al., 1997)? Nrg2 null mutant mice are myelinated (Britto et al., 2004), but coexpression of NRG1 and NRG2 within the CNS is limited (Busfield et al., 1997; Longart et al., 2004) (Lai et al., unpublished data). Moreover, transgenic overexpression of NRG2 failed to increase myelin thickness in the CNS (T.M.F., M.H.S., C.L., and K.A.N., unpublished observation). Thirdly, NRG2 is expressed in both motoneurons (Rimer et al., 2004) and DRG neurons (Fig. S6E), but obviously fails to compensate for the lack of NRG1 expression in the PNS. Another candidate for compensation is Neuregulin-3 (NRG3), a more distantly-related growth factor that is widely expressed in the CNS (Zhang et al., 1997). Again, NRG3 null mutants are viable and normally myelinated (T.M., A.G and C.B., unpublished observation). All this is in agreement with normal myelination of conditional ErbB3*ErbB4 double mutant mice.

Interestingly, a mild CNS hypomyelination (in addition to peripheral dysmyelination) was reported for Bace1 mutant mice (Hu et al., 2006). While PNS effects in these mice are likely NRG1-dependent (Willem et al., 2006), our data suggest that in the CNS other proteins must be the relevant BACE1 targets. Not only could the unknown signal of CNS myelination require proteolytic cleavage. Also the β2 subunit of the voltage-gated sodium channel (Kim et al., 2007) is a candidate for BACE1 processing, as timely myelination requires the electrical activity of axons.

In contrast to our observations in loss-of-function mutants, the neuronal overexpression of NRG1 in transgenic mice stimulated myelination, with little difference between NRG1 type III and type I isoforms. Perinatal overexpression of NRG1 type III also increased the soma size of oligodendrocytes. In contrast, proliferation of oligodendrocyte precursors was unaltered. Thus, neuronal NRG1 type III (even at severalfold elevated expression levels) appears ineffective in stimulating OPC proliferation. We hypothesize that NRG1 promotes oligodendrocyte growth by activating the PI3K/TOR/S6K pathway, because a similar ‘uncoupling’ of oligodendrocyte proliferation and differentiation is observed in conditional mutants of the Pten gene (S.G. and KAN, unpublished observations).

That overexpression of NRG1 in retinal ganglion cells causes even premature myelination of the optic nerve is remarkable. It addresses the question whether myelination is developmentaly controlled by neuronal/axonal or oligodendroglial differentiation. Our experiments reveal that manipulating neuronal differentiation is sufficient to trigger premature myelination, implying that oligodendrocytes are already myelination competent and thus "waiting" for axonal signals. The remyelination experiments further reveal that oligodendrocytes loose this responsiveness to NRG1 at an older age. This is in marked difference to Schwann cells that occasionally invade the same CNS lesion where they clearly hypermyelinate the NRG1 type III overexpressing axons (not shown).

Possible roles of NRG1/ErbB signalling in oligodendrocytes

If not required for myelination, are other oligodendroglial functions regulated by neuregulins in the CNS? Oligodendrocytes and NG2+ precursor cells are known to express NMDA, AMPA and kainate receptors, similar to neurons and astrocytes, which coexpress ErbB4 with these glutamate receptors (Wong, 2006; Verkhratsky and Kirchhoff, 2007). Since NRG1/ErbB signalling has been implicated in the subcellular targeting and endocytosis of synaptic glutamate receptors (Gu et al., 2005; Kwon et al., 2005), it may serve a similar function for glutamate receptors on oligodendrocytes.

NRG1 may also have more subtle functions in the plasticity of cortical myelination. This relates to our observation of a 2-fold higher density of myelinated axons within the neocortex of Nrg1-transgenic mice (a number unmatched by an increase of oligodendrocyte density). Does NRG1 stimulate the generation of myelinating glial processes? Cultured neurons and oligodendrocytes reportedly increase the number of processes when NRG1 is added to the medium (Canoll et al., 1999; Canoll et al., 1996). However, by three-dimensional cell tracing, cortical oligodendrocytes revealed about the same number of primary and secondary branches (per cell), independent of the axonal NRG1 expression level. Thus, the increased ‘myelin-to-oligodendrocyte’ ratio is more likely caused by slightly longer internodes (which are virtually impossible to quantify in the cortex).

In conclusion, our data suggest that CNS evolution has made vertebrate oligodendrocytes independent from NRG1, presumably the ancestral signal on axons that is necessary and sufficient for myelination by Schwann cells. Perhaps, a simple system (represented by NRG1 type III/ErbB signalling to Schwann cells) has been superseded in the CNS by a complex system that includes neuronal activity as a myelination signal. Recently identified signaling components that serve different roles in CNS and PNS myelination include (activity-dependent release of) ATP and purinergic receptors (Fields and Burnstock, 2006; Stevens et al., 2002). That CNS and PNS employ distinct mechanisms of glial specification and myelination control is consistent with distinct responses of oligodendrocytes and Schwann cells to neurotrophins (Chan et al., 2004).

Relevance to neuropsychiatric disease

With respect to human disease, Nrg1 is an attractive susceptibility gene for schizophrenia (Stefansson et al., 2002), because this factor has been implicated in neuronal migration, synaptic plasticity, and myelination, all processes independently associated with schizophrenia (Bartzokis, 2002; Corfas et al., 2004). In particular, cortical white matter abnormalities have been repeatedly reported in SZ patients, which includes the reduced expression of myelin-related genes (Hakak et al, 2001; Tkachev et al., 2003) and decreased fractional anisotropy of callosal fibers by diffusion tensor imaging (reviewed in Dwork et al., 2007). While altered NRG1 expression levels could be a plausible cause and ‘missing link’ to epidemiological data, our observation in mutant mice suggests otherwise. Even conditional Nrg1 null mutants revealed quantitatively normal expression levels of structural myelin proteins (by western blotting or qRT-PCR) and also the CNS myelin ultrastructure was unaltered. Although it is difficult to make predictions across species, these data suggest that small alterations of NRG1 expression, as predicted for the NRG1 at risk haplotype in humans, is highly unlikely to explain the white matter abnormalities independently documented in schizophrenia patients (Davis et al., 2003). However, several of the mouse mutants described here will be useful to study other schizophrenia-relevant functions in vivo, such as the role of the Nrg1 gene in synaptic plasticity and cognitive functions.

Experimental Procedures

Transgenic and mutant mice

The generation and genotyping of mice with null alleles of Nrg1 (Meyer et al., 1997), ErbB3 (Riethmacher et al., 1997), and ErbB4 (Tidcombe et al., 2003), conditional null alleles of Nrg1 (Li et al., 2002), ErbB3 (T.M. and C.B. unpublished), and ErbB4 (Golub et al., 2004) and Nrg1 type I and type III transgenes (Michailov et al., 2004) have been described. Floxed alleles of Nrg1 are genetically null for alpha-NRG1 isoforms, but based on normal g-ratios in comparison to wildtype and Nrg1 null heterozygotes (not shown) they can be considered controls.

Cre driver lines Nestin-Cre (Tronche et al., 1999), Emx1-Cre (Gorski et al., 2002) NEX-Cre (Goebbels et al., 2006), CamKII alpha-Cre (Minichiello et al., 1999) and CNP-Cre (Lappe-Siefke et al., 2003) and Cre reporter lines R26R-lacZ (Soriano, 1999) and floxtauGFP-lacZ (Hippenmeyer et al., 2005) were also genotyped as described. For PCR, we isolated genomic DNA from tail biopsies, using Invisorb Spin tissue Mini Kit (Invitek), according to the manufacturer's directions. For routine genotyping, we used PCR primers in a coamplification reaction. Primer sequences are available upon request. All animal experiments were carried out in compliance with approved animal policies of the Max Planck Institute of Experimental Medicine.

RNA analysis

Total RNA was extracted using Qiazol Reagent according to the manufacturer (Qiagen). The integrity of purified RNA was confirmed using the Agilent 2100 Bioanalyser (Agilent Technologies). For RT-PCR analysis, cDNA was synthesized from total RNA using random nonamer primers and Superscript III RNase H reverse transcriptase (Invitrogen). Quantitative real-time PCR was carried out using the ABI Prism 7700 Sequence Detection System and SYBR Green Master Mix according to the manufacturer (Applied Biosystems). Reactions were carried out at least in triplicates. The relative quantity (RQ) of RNA was calculated using 7500 Fast System SDS software Ver 1.3 (Applied Biosystems). Results were depicted as histograms (generated by Microsoft-Excel 2003) of normalized RQ values, with maximum RQ value in a given group normalized to 100%. PCR primer sequences are available upon request.

Protein Analysis

Protein lysates were prepared using an Ultraturrax (T8). Tissues were homogenized in 1 ml of modified RIPA buffer and protease inhibitors (Complete tablets, Roche). For Western Blotting 50 µg (for NRG1) or 1–5 µg (for myelin proteins) of cortical or total brain lysate was size-separated on 8–10% (NRG1) or 12% (myelin proteins) SDS-polyacrylamide gels and blotted onto PVDF membranes (Hybond™-P) following instructions from Invitrogen. Membranes were incubated with primary antibodies as described in supplemental data. The densitometeric analysis of scanned ECL films was carried out using QuantityOne® and ImageJ software from BioRad.

Histology and immunostaining

Mice (P7 and older) were anesthetized with avertin and perfused with 4% paraformaldehyde in 0.1M PBS. Brains, spinal cords and sciatic nerves were postfixed in 4% paraformaldehyde for one hour to overnight at 4°C and embedded in paraplast. Microtome sections (5–7 µm) were Haematoxylin-Eosin (H&E) or Nissl stained for studying brain cytoarchitecture. Myelinated fibers were visualized by Gallyas silver staining. Axonal architecture of the neocortex was studied by Bielschowsky silver impregnation. For immunofluorescent staining, paraffin sections were incubated overnight with primary antibodies against CNP (mM; 1:150, Sigma), GFAP (pRb; 1:200, DAKO), MBP (pRb; 1:500; DAKO), CC-1 (mM; 1:50; Calbiochem), NeuN (mM; 1:100, Chemicon), Olig2 (pRb; 1:20,000, a gift of C. Stiles), FNP7 (mM; 1:150, Zytomed Systems), Krox20 (pRb; 1:400, a gift of D. Meijer), NRG1 (pRb; 1:100, Santa Cruz Biotech) and MPZ (mM; 1:1000, a gift from J.J. Archelos). Sections were further incubated with their corresponding secondary Cy2 (1:100, Jackson ImmunoResearch) or Cy3 (1:1000, Jackson ImmunoResearch) antibody for 1 hour at room temperature. For DAB based immunostaining the Dako-LSAB2 kit was used according to manufacturer's instructions. Digital images of stained sections were obtained using Axiophot (Zeiss, Germany) and DMRXA (Leica, Germany) microscopes and Openlab 3.1.1 software (Improvision). All images were processed with Photoshop CS and Illustrator 10 software (Adobe).

Imaging oligodendrocyte morphology

Sections were immunostained as described in supplemental data. A Zeiss laser scanning confocal microscope (Meta 510) was used to acquire z-stacks of OLs at optical slices of 0.53 µm with a 63X objective (1.4 numerical aperture). Confocal z-stacks were used to trace 12–15 individual OLs per genotype (from n=3 mice each) with the AutoNeuron software package from the Neurolucida three-dimensional cell tracing system (MBF Biosciences, Williston, VT). Cell tracings were analysed with the Neuroexplorer software (MBF Biosciences, Williston, VT). Statistical Data analysis (two tailed t test with Welch's correction and 1 way ANOVA test or kruskal-walli's test) was performed using the GraphPad Prism software package.

Electron microscopy and morphometry

Mice were perfused with 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1M PBS. Spinal cord, cortex, corpus callosum, optic nerves and sciatic nerves were removed, contrasted with osmium tetroxide and Epon embedded. Semi-thin sections (0.5 µm) were cut using a microtome (Leica, RM 2155) with a diamond knife (Histo HI 4317, Diatome). Sections were stained with azur II-methylenblue for 1 min at 60°C. Light microscopic observation was with a 100x lens (Leica DMRXA) and images were digitalized and analyzed with Openlab 3.1.1 and Scian Image software. For electron microscopy of cortex, corpus callosum, optic nerve and sciatic nerve ultrathin (50–70 nm) sections were stained with 1% uranylacetate solution and analysed using a Zeiss EM10 or EM109 (Leo). The g-ratio was determined by dividing the circumference of an axon (without myelin) by the circumference of the same axon including myelin. At least 100 fibers per animal were analyzed, using 3–6 animals per genotype. Statistical analyses were performed using Statistica 6.0 (StatSoft, Tulsa, USA).

Supplementary Material

01

Acknowledgements

We thank A. Fahrenholz and P. Soban for help with histology, G. Fricke-Bode for cell culture work, W. Möbius, T. Ruhwedel, and C. Griffel for help with electron microscopy, and I. Bormuth for brain sections of NEXCre*floxtau-GFP-lacZ mice. We thank S. Emme, M. Schindler, and S. Thiel (MPI, Göttingen) for generating transgenic mice, E. Rhode (MDC Berlin) for help with ES cell culture, P. Stallerow and C. Päseler (MDC Berlin) for help with animal husbandry, and B. Jerchow and K. Becker for blastocyst injections. We also thank M. Gassman for providing ErbB4 mutants, R. Klein for CamKII-Cre mice, G. Schütz for Nestin-Cre mice, K. Jones for Emx-Cre mice, and S. Arber for floxtau-GFP-lacZ mice. We acknowledge C. Stiles for Olig2 antibody, M. Less for PLP antibody 3F4, D. Meijer for Krox20 antibody, J.J. Archelos for MPZ antibody, and J. Salzer, M. Simons, and members of the Nave lab for helpful discussions. K.A.N. acknowledges grant support from the Deutsche Forschungsgemeinschaft (CMPB), the National Multiple Sclerosis Society, the Hertie Institute of MS Research, the Myelin Project, and the BMBF. C. B., T.M., A.G. and H.W. are supported by grants from the Deutsche Forschungsgemeinschaft (SFB 665) and the BMBF. C.L. is supported by the National Institutes of Health (NS32367). We dedicate this paper to the memory of C.H. who tragically died.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Adlkofer K, Lai C. Role of neuregulins in glial cell development. Glia. 2000;29:104–111. [PubMed]
  • Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci. 2007;10:990–1002. [PubMed]
  • Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology. 2002;27:672–683. [PubMed]
  • Britto JM, Lukehurst S, Weller R, Fraser C, Qiu Y, Hertzog P, Busfield SJ. Generation and characterization of neuregulin-2-deficient mice. Mol Cell Biol. 2004;24:8221–8226. [PMC free article] [PubMed]
  • Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA, Comrack CA, Dussault BJ, Woolf J, Goodearl AD, Gearing DP. Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol. 1997;17:4007–4014. [PMC free article] [PubMed]
  • Calaora V, Rogister B, Bismuth K, Murray K, Brandt H, Leprince P, Marchionni M, Dubois-Dalcq M. Neuregulin signaling regulates neural precursor growth and the generation of oligodendrocytes in vitro. J Neurosci. 2001;21:4740–4751. [PubMed]
  • Canoll PD, Kraemer R, Teng KK, Marchionni MA, Salzer JL. GGF/neuregulin induces a phenotypic reversion of oligodendrocytes. Mol Cell Neurosci. 1999;13:79–94. [PubMed]
  • Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron. 1996;17:229–243. [PubMed]
  • Carraway KL, 3rd, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature. 1997;387:512–516. [PubMed]
  • Chan JR, Watkins TA, Cosgaya JM, Zhang C, Chen L, Reichardt LF, Shooter EM, Barres BA. NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes. Neuron. 2004;43:183–191. [PMC free article] [PubMed]
  • Colello RJ, Pott U. Signals that initiate myelination in the developing mammalian nervous system. Mol Neurobiol. 1997;15:83–100. [PubMed]
  • Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci. 2004;7:575–580. [PubMed]
  • Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60:443–456. [PubMed]
  • Duncan ID, Hoffman RL. Schwann cell invasion of the central nervous system of the myelin mutants. J Anat. 1997;190(Pt 1):35–49. [PubMed]
  • Dwork AJ, Mancevski B, Rosoklija G. White matter and cognitive function in schizophrenia. Int J Neuropsychopharmacol. 2007;10:513–536. [PubMed]
  • Esper RM, Pankonin MS, Loeb JA. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Brain Res Rev. 2006;51:161–175. [PubMed]
  • Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14–30. [PubMed]
  • Fernandez PA, Tang DG, Cheng L, Prochiantz A, Mudge AW, Raff MC. Evidence that axon-derived neuregulin promotes oligodendrocyte survival in the developing rat optic nerve. Neuron. 2000;28:81–90. [PubMed]
  • ffrench-Constant C, Colognato H, Franklin RJ. Neuroscience. The mysteries of myelin unwrapped. Science. 2004;304:688–689. [PubMed]
  • Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci. 2006;7:423–436. [PMC free article] [PubMed]
  • Flames N, Long JE, Garratt AN, Fischer TM, Gassmann M, Birchmeier C, Lai C, Rubenstein JL, Marin O. Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron. 2004;44:251–261. [PubMed]
  • Flores AI, Mallon BS, Matsui T, Ogawa W, Rosenzweig A, Okamoto T, Macklin WB. Akt-mediated survival of oligodendrocytes induced by neuregulins. J Neurosci. 2000;20:7622–7630. [PubMed]
  • Garratt AN, Britsch S, Birchmeier C. Neuregulin, a factor with many functions in the life of a schwann cell. Bioessays. 2000a;22:987–996. [PubMed]
  • Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C. A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool. J Cell Biol. 2000b;148:1035–1046. [PMC free article] [PubMed]
  • Goebbels S, Bormuth I, Bode U, Hermanson O, Schwab MH, Nave KA. Genetic targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice. Genesis. 2006;44:611–621. [PubMed]
  • Golub MS, Germann SL, Lloyd KC. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res. 2004;153:159–170. [PubMed]
  • Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JL, Jones KR. Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J Neurosci. 2002;22:6309–6314. [PubMed]
  • Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci. 2005;25:4974–4984. [PubMed]
  • Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98:4746–4751. [PubMed]
  • Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL, Thomson PA, Porteous DJ, Cunningham-Owens DG, Johnstone EC, Lawrie SM. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci. 2006;9:1477–1478. [PubMed]
  • Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR, Arber S. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS biology. 2005;3:e159. [PubMed]
  • Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520–1525. [PubMed]
  • Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci. 2005;6:671–682. [PubMed]
  • Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol. 1999;147:77–88. [PMC free article] [PubMed]
  • Kagawa T, Ikenaka K, Inoue Y, Kuriyama S, Tsujii T, Nakao J, Nakajima K, Aruga J, Okano H, Mikoshiba K. Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron. 1994;13:427–442. [PubMed]
  • Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, Kovacs DM. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755–764. [PMC free article] [PubMed]
  • Kim JY, Sun Q, Oglesbee M, Yoon SO. The role of ErbB2 signaling in the onset of terminal differentiation of oligodendrocytes in vivo. J Neurosci. 2003;23:5561–5571. [PubMed]
  • Kwon OB, Longart M, Vullhorst D, Hoffman DA, Buonanno A. Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. J Neurosci. 2005;25:9378–9383. [PubMed]
  • Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33:366–374. [PubMed]
  • Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proc Natl Acad Sci U S A. 2006;103:6747–6752. [PubMed]
  • Li L, Cleary S, Mandarano MA, Long W, Birchmeier C, Jones FE. The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland. Oncogene. 2002;21:4900–4907. [PubMed]
  • Longart M, Liu Y, Karavanova I, Buonanno A. Neuregulin-2 is developmentally regulated and targeted to dendrites of central neurons. J Comp Neurol. 2004;472:156–172. [PubMed]
  • Lopez-Bendito G, Cautinat A, Sanchez JA, Bielle F, Flames N, Garratt AN, Talmage DA, Role LW, Charnay P, Marin O, Garel S. Tangential neuronal migration controls axon guidance: a role for neuregulin-1 in thalamocortical axon navigation. Cell. 2006;125:127–142. [PMC free article] [PubMed]
  • Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437–452. [PMC free article] [PubMed]
  • Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE, Birchmeier C. Isoform-specific expression and function of neuregulin. Development. 1997;124:3575–3586. [PubMed]
  • Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004;304:700–703. [PubMed]
  • Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein R. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron. 1999;24:401–414. [PubMed]
  • Nave KA, Salzer JL. Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol. 2006;16:492–500. [PubMed]
  • Park SK, Miller R, Krane I, Vartanian T. The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. J Cell Biol. 2001;154:1245–1258. [PMC free article] [PubMed]
  • Penderis J, Woodruff RH, Lakatos A, Li WW, Dunning MD, Zhao C, Marchionni M, Franklin RJ. Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur J Neurosci. 2003;18:2253–2264. [PubMed]
  • Readhead C, Schneider A, Griffiths I, Nave KA. Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron. 1994;12:583–595. [PubMed]
  • Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 1997;389:725–730. [PubMed]
  • Rimer M, Prieto AL, Weber JL, Colasante C, Ponomareva O, Fromm L, Schwab MH, Lai C, Burden SJ. Neuregulin-2 is synthesized by motor neurons and terminal Schwann cells and activates acetylcholine receptor transcription in muscle cells expressing ErbB4. Mol Cell Neurosci. 2004;26:271–281. [PubMed]
  • Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, Benoit-Marand M, Chen C, Moore H, O'Donnell P, et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci U S A. 2007;104:8131–8136. [PubMed]
  • Sagane K, Hayakawa K, Kai J, Hirohashi T, Takahashi E, Miyamoto N, Ino M, Oki T, Yamazaki K, Nagasu T. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci. 2005;6:33. [PMC free article] [PubMed]
  • Schmucker J, Ader M, Brockschnieder D, Brodarac A, Bartsch U, Riethmacher D. erbB3 is dispensable for oligodendrocyte development in vitro and in vivo. Glia. 2003;44:67–75. [PubMed]
  • Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nature genetics. 1999;21:70–71. [PubMed]
  • Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877–892. [PubMed]
  • Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron. 2002;36:855–868. [PMC free article] [PubMed]
  • Sussman CR, Vartanian T, Miller RH. The ErbB4 neuregulin receptor mediates suppression of oligodendrocyte maturation. J Neurosci. 2005;25:5757–5762. [PubMed]
  • Taveggia C, Thaker P, Petrylak A, Caporaso GL, Toews A, Falls DL, Einheber S, Salzer JL. Type III neuregulin-1 promotes oligodendrocyte myelination. Glia. 2008;56:284–293. [PubMed]
  • Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron. 2005;47:681–694. [PMC free article] [PubMed]
  • Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci U S A. 2003;100:8281–8286. [PubMed]
  • Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798–805. [PubMed]
  • Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99–103. [PubMed]
  • Tuohy TM, Wallingford N, Liu Y, Chan FH, Rizvi T, Xing R, Bebo B, Rao MS, Sherman LS. CD44 overexpression by oligodendrocytes: a novel mouse model of inflammation-independent demyelination and dysmyelination. Glia. 2004;47:335–345. [PubMed]
  • Turnley AM, Morahan G, Okano H, Bernard O, Mikoshiba K, Allison J, Bartlett PF, Miller JF. Dysmyelination in transgenic mice resulting from expression of class I histocompatibility molecules in oligodendrocytes. Nature. 1991;353:566–569. [PubMed]
  • Vartanian T, Fischbach G, Miller R. Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. Proc Natl Acad Sci U S A. 1999;96:731–735. [PubMed]
  • Vartanian T, Goodearl A, Viehover A, Fischbach G. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J Cell Biol. 1997;137:211–220. [PMC free article] [PubMed]
  • Verkhratsky A, Kirchhoff F. NMDA Receptors in glia. Neuroscientist. 2007;13:28–37. [PubMed]
  • Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664–666. [PubMed]
  • Wolpowitz D, Mason TB, Dietrich P, Mendelsohn M, Talmage DA, Role LW. Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron. 2000;25:79–91. [PubMed]
  • Wong R. NMDA receptors expressed in oligodendrocytes. Bioessays. 2006;28:460–464. [PubMed]
  • Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A. 1997;94:9562–9567. [PubMed]